University of California Davis Medical Center ( Site 1064) — Sherman Oaks, California

University of California Davis Medical Center ( Site 1064) is a clinical research site located in Sherman Oaks, California, United States 95817.

Crixeo Clinical Trials Trust Score: 80/100 (GOOD). This profile has not yet been claimed by the site owner.

University of California Davis Medical Center ( Site 1064) has participated in 2 clinical trials.

Therapeutic areas: Pulmonary Arterial Hypertension.

Sponsors: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Sherman Oaks

Browse all research sites in California · View every site in Sherman Oaks

Sponsor Feasibility Report

Trust Score: 80/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for University of California Davis Medical Center ( Site 1064)?

University of California Davis Medical Center ( Site 1064) has a Crixeo Trust Score of 80/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has University of California Davis Medical Center ( Site 1064) conducted?

University of California Davis Medical Center ( Site 1064) has 2 clinical trials on record. Their work covers Pulmonary Arterial Hypertension.

Is University of California Davis Medical Center ( Site 1064) accredited by Crixeo Clinical Trials?

University of California Davis Medical Center ( Site 1064) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about University of California Davis Medical Center ( Site 1064)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.